BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 10398427)

  • 21. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.
    Borg A; Sandberg T; Nilsson K; Johannsson O; Klinker M; Måsbäck A; Westerdahl J; Olsson H; Ingvar C
    J Natl Cancer Inst; 2000 Aug; 92(15):1260-6. PubMed ID: 10922411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.
    McKenzie HA; Fung C; Becker TM; Irvine M; Mann GJ; Kefford RF; Rizos H
    Hum Mutat; 2010 Jun; 31(6):692-701. PubMed ID: 20340136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation.
    Molven A; Grimstvedt MB; Steine SJ; Harland M; Avril MF; Hayward NK; Akslen LA
    Genes Chromosomes Cancer; 2005 Sep; 44(1):10-8. PubMed ID: 15880589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lack of germline CDK6 mutations in familial melanoma.
    Shennan MG; Badin AC; Walsh S; Summers A; From L; McKenzie M; Goldstein AM; Tucker MA; Hogg D; Lassam N
    Oncogene; 2000 Mar; 19(14):1849-52. PubMed ID: 10777219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families.
    Yakobson E; Shemesh P; Azizi E; Winkler E; Lassam N; Hogg D; Brookes S; Peters G; Lotem M; Zlotogorski A; Landau M; Safro M; Shafir R; Friedman E; Peretz H
    Eur J Hum Genet; 2000 Aug; 8(8):590-6. PubMed ID: 10951521
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup.
    Bruno W; Pastorino L; Ghiorzo P; Andreotti V; Martinuzzi C; Menin C; Elefanti L; Stagni C; Vecchiato A; Rodolfo M; Maurichi A; Manoukian S; De Giorgi V; Savarese I; Gensini F; Borgognoni L; Testori A; Spadola G; Mandalà M; Imberti G; Savoia P; Astrua C; Ronco AM; Farnetti A; Tibiletti MG; Lombardo M; Palmieri G; Ayala F; Ascierto P; Ghigliotti G; Muggianu M; Spagnolo F; Picasso V; Tanda ET; Queirolo P; Bianchi-Scarrà G
    J Am Acad Dermatol; 2016 Feb; 74(2):325-32. PubMed ID: 26775776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genomic rearrangements of the CDKN2A locus are infrequent in Italian malignant melanoma families without evidence of CDKN2A/CDK4 point mutations.
    Vignoli M; Scaini MC; Ghiorzo P; Sestini R; Bruno W; Menin C; Gensini F; Piazzini M; Testori A; Manoukian S; Orlando C; D'Andrea E; Bianchi-Scarrà G; Genuardi M
    Melanoma Res; 2008 Dec; 18(6):431-7. PubMed ID: 19011513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel CDKN2A mutation detected in Spanish melanoma pedigree.
    de Torre C; Martínez-Escribano J
    Exp Dermatol; 2010 Aug; 19(8):e333-5. PubMed ID: 20653773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma.
    Soufir N; Lacapere JJ; Bertrand G; Matichard E; Meziani R; Mirebeau D; Descamps V; Gérard B; Archimbaud A; Ollivaud L; Bouscarat F; Baccard M; Lanternier G; Saïag P; Lebbé C; Basset-Seguin N; Crickx B; Cave H; Grandchamp B
    Br J Cancer; 2004 Jan; 90(2):503-9. PubMed ID: 14735200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect.
    Auroy S; Avril MF; Chompret A; Pham D; Goldstein AM; Bianchi-Scarrà G; Frebourg T; Joly P; Spatz A; Rubino C; Demenais F; Bressac-de Paillerets B;
    Genes Chromosomes Cancer; 2001 Nov; 32(3):195-202. PubMed ID: 11579459
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CDKN2A germline splicing mutation affecting both p16(ink4) and p14(arf) RNA processing in a melanoma/neurofibroma kindred.
    Petronzelli F; Sollima D; Coppola G; Martini-Neri ME; Neri G; Genuardi M
    Genes Chromosomes Cancer; 2001 Aug; 31(4):398-401. PubMed ID: 11433531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Several noncontiguous domains of CDK4 are involved in binding to the P16 tumor suppressor protein.
    Ceha HM; Nasser I; Medema RH; Slebos RJ
    Biochem Biophys Res Commun; 1998 Aug; 249(2):550-5. PubMed ID: 9712735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of Latvian familial melanoma patients shows novel variants in the noncoding regions of CDKN2A and that the CDK4 mutation R24H is a founder mutation.
    Veinalde R; Ozola A; Azarjana K; Molven A; Akslen LA; Doniņa S; Proboka G; Cēma I; Baginskis A; Pjanova D
    Melanoma Res; 2013 Jun; 23(3):221-6. PubMed ID: 23546221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CDKN2A germline mutations in U.K. patients with familial melanoma and multiple primary melanomas.
    MacKie RM; Andrew N; Lanyon WG; Connor JM
    J Invest Dermatol; 1998 Aug; 111(2):269-72. PubMed ID: 9699728
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CDKN2A mutations in melanoma families from Uruguay.
    Larre Borges A; Cuéllar F; Puig-Butillé JA; Scarone M; Delgado L; Badenas C; Milà M; Malvehy J; Barquet V; Núñez J; Laporte M; Fernández G; Levrero P; Martínez-Asuaga M; Puig S
    Br J Dermatol; 2009 Sep; 161(3):536-41. PubMed ID: 19523171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma.
    Edmunds SC; Kelsell DP; Hungerford JL; Cree IA
    Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):2845-51. PubMed ID: 12202501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CDKN2A/p16 is inactivated in most melanoma cell lines.
    Castellano M; Pollock PM; Walters MK; Sparrow LE; Down LM; Gabrielli BG; Parsons PG; Hayward NK
    Cancer Res; 1997 Nov; 57(21):4868-75. PubMed ID: 9354451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutation analysis of the CDKN2A promoter in Australian melanoma families.
    Pollock PM; Stark MS; Palmer JM; Walters MK; Aitken JF; Martin NG; Hayward NK
    Genes Chromosomes Cancer; 2001 Sep; 32(1):89-94. PubMed ID: 11477665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein.
    Sun S; Pollock PM; Liu L; Karimi S; Jothy S; Milner BJ; Renwick A; Lassam NJ; Hayward NK; Hogg D; Narod SA; Foulkes WD
    Int J Cancer; 1997 Nov; 73(4):531-6. PubMed ID: 9389568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional impairment of melanoma-associated p16(INK4a) mutants in melanoma cells despite retention of cyclin-dependent kinase 4 binding.
    Becker TM; Rizos H; Kefford RF; Mann GJ
    Clin Cancer Res; 2001 Oct; 7(10):3282-8. PubMed ID: 11595726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.